News Website

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Business Wire

Published: Oct. 27, 2025, 7:33 p.m.

Read Full Article

Hutchmed’s Promising Phase III Study on Advanced Endometrial Cancer Treatment - TipRanks

Hutchmed’s Promising Phase III Study on Advanced Endometrial Cancer Treatment TipRanks

Published: Oct. 27, 2025, 5:04 p.m.

Read Full Article

Predicted peptide scaffolds for drug screening in endometrial cancer organoids - Nature

Predicted peptide scaffolds for drug screening in endometrial cancer organoids Nature

Published: Oct. 27, 2025, 2:22 p.m.

Read Full Article

Diagnostic Accuracy of Endometrial Sampling Methods for Determining Histologic Type and Grade in Endometrial Cancer: A Retrospective Cohort Study - Cureus

Diagnostic Accuracy of Endometrial Sampling Methods for Determining Histologic Type and Grade in Endometrial Cancer: A Retrospective Cohort Study Cureus

Published: Oct. 26, 2025, 10:10 a.m.

Read Full Article

Researchers identify common painkiller that may prevent endometrial cancer - Daily Nation

Researchers identify common painkiller that may prevent endometrial cancer Daily Nation

Published: Oct. 26, 2025, 10 a.m.

Read Full Article

Correction: Endometrial cancer (EC) derived G3BP1 overexpression and mutant promote EC tumorigenesis and metastasis via SPOP/ERα axis - Cell Communication and Signaling

Correction: Endometrial cancer (EC) derived G3BP1 overexpression and mutant promote EC tumorigenesis and metastasis via SPOP/ERα axis Cell Communication and Signaling

Published: Oct. 24, 2025, 12:50 p.m.

Read Full Article

WES-Aneuploidy Scores May Be Prognostic for Immunotherapy in dMMR Endometrial Cancer - OncLive

WES-Aneuploidy Scores May Be Prognostic for Immunotherapy in dMMR Endometrial Cancer OncLive

Published: Oct. 23, 2025, 6:03 p.m.

Read Full Article

Endometrial Cancer and Body Image: How to Cope and Rebuild Confidence - Everyday Health

Endometrial Cancer and Body Image: How to Cope and Rebuild Confidence Everyday Health

Published: Oct. 22, 2025, 7:12 p.m.

Read Full Article

Frontline Strategy: Why You Must Use IO Upfront in Endometrial Cancer - Targeted Oncology

Frontline Strategy: Why You Must Use IO Upfront in Endometrial Cancer Targeted Oncology

Published: Oct. 22, 2025, 6:21 p.m.

Read Full Article

Endometrial Cancer: Dostarlimab/Chemo Improves OS in Frontline RUBY Trial - Targeted Oncology

Endometrial Cancer: Dostarlimab/Chemo Improves OS in Frontline RUBY Trial Targeted Oncology

Published: Oct. 22, 2025, 5:11 p.m.

Read Full Article

Latest Articles

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire

Hutchmed’s Promising Phase III Study on Advanced Endometrial Cancer Treatment - TipRanks

Predicted peptide scaffolds for drug screening in endometrial cancer organoids - Nature

Diagnostic Accuracy of Endometrial Sampling Methods for Determining Histologic Type and Grade in Endometrial Cancer: A Retrospective Cohort Study - Cureus

Researchers identify common painkiller that may prevent endometrial cancer - Daily Nation

Correction: Endometrial cancer (EC) derived G3BP1 overexpression and mutant promote EC tumorigenesis and metastasis via SPOP/ERα axis - Cell Communication and Signaling

WES-Aneuploidy Scores May Be Prognostic for Immunotherapy in dMMR Endometrial Cancer - OncLive

Endometrial Cancer and Body Image: How to Cope and Rebuild Confidence - Everyday Health

Frontline Strategy: Why You Must Use IO Upfront in Endometrial Cancer - Targeted Oncology

Endometrial Cancer: Dostarlimab/Chemo Improves OS in Frontline RUBY Trial - Targeted Oncology

Subscribe to Our Newsletter